Madrigal Pharmaceuticals – Consensus Indicates Potential 43.7% Upside

Broker Ratings

Madrigal Pharmaceuticals found using ticker (MDGL) have now 14 analysts in total covering the stock. The consensus rating is ‘Buy’. The range between the high target price and low target price is between 230 and 123 calculating the average target price we see 170. With the stocks previous close at 118.34 this now indicates there is a potential upside of 43.7%. There is a 50 day moving average of 120.66 and the 200 moving average now moves to 114.83. The company has a market cap of $1,824m. Company Website: http://www.madrigalpharma.com

Madrigal Pharmaceuticals, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic candidates for the treatment of cardiovascular, metabolic, and liver diseases. The company’s lead candidate is MGL-3196, an orally administered, small-molecule, liver-directed, thyroid hormone receptor (THR) ß-selective agonist, which is in Phase III clinical trials for the treatment of non-alcoholic steatohepatitis (NASH). It is also developing MGL-3745, a THR-ß-selective small molecule that is in preclinical trials for the treatment of NASH and hyperlipidemia. The company has research, development, and commercialization agreement with Hoffmann-La Roche to develop, use, sell, offer for sale, and import various licensed products. Madrigal Pharmaceuticals was founded in 2011 and is headquartered in West Conshohocken, Pennsylvania.

You can now share this on Stocktwits, just click the logo below and add the ticker in the text to be seen.

Share on Stocktwits

Good news travels fast (but only if you make that happen):

Share on twitter
Twitter
Share on linkedin
LinkedIn
Share on facebook
Facebook
Share on email
Email
Share on whatsapp
WhatsApp

AIM All Share Index